Fig. 2

Production of bFGF protein and characterization of the prepared HSA-bFGF NPs. (A) Construction of E. coli expression vector, pET-28a/FGF2-G3. (B) Three-dimensional representation structure of bFGF protein. (C) SDS-PAGE analysis of the purified recombinant bFGF protein. M means marker. Red arrow indicates bFGF protein. (D) Western blot analysis of bFGF protein produced from E. coli. M means marker. Red arrow indicates bFGF protein. (E) Schematic illustrations demonstrating formation of HSA-bFGF NPs via crosslinking between HSA and bFGF mediated by GA. (F) Nanoparticle size and PI depending on the bFGF contents (wt%) in HSA-bFGF NPs. (G) Zeta-potential changes of the HSA-bFGF NPs. (H) SEM images of HSA-bFGF NPs containing 0 or 25 wt% of bFGF protein, respectively. Scale bars, 500 nm. (I) In vitro release profile of bFGF from HSA-bFGF NPs depending upon the amount of added crosslinker, GA